U.S. pharma big copyright scrapped two experimental weight loss drugs last year—a at the time-every day capsule, lotiglipron, as a result of elevated liver enzymes and a two times-every day capsule, danuglipron, as a consequence of sturdy Negative effects—but CEO Albert Bourla has explained the company is set to “Enjoy and gain” in the bein